Applied BioCode Corporation (TPE:6598)

Market Cap	1.96B
Revenue (ttm)	343.07M
Net Income (ttm)	-260.81M
Shares Out	102.79M
EPS (ttm)	-2.88
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	43,175
Average Volume	125,365
Open	19.45
Previous Close	19.10
Day's Range	19.10 - 19.45
52-Week Range	17.00 - 33.60
Beta	0.51
RSI	43.25
Earnings Date	May 12, 2025

About Applied BioCode

Applied BioCode Corporation designs, develops, and commercializes multiplex diagnostic testing products in California. The company’s products include the BioCode MDx 3000 system, an automated molecular diagnostic system that automates the PCR amplification, hybridization, and detection steps of molecular testing; and the BioCode 2500 analyzer, a system that reads barcoded magnetic beads (BMB) and displays the barcode and fluorescence intensity for each BMB. It develops assays, such as BioCode SARS-CoV-2 Assay, a nucleic acid assay for the detec...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: Winston Z. Ho
• Country: Cayman Islands
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6598

Financial Performance

In 2024, Applied BioCode's revenue was 343.07 million, a decrease of -13.18% compared to the previous year's 395.17 million. Losses were -260.81 million, 58.8% more than in 2023.